TABLE 3.
Odds ratios (ORs) of prostate cancer according to quartiles (Q) of serum selenium, overall and by tumor characteristics1
| Serum selenium
|
|||||
|---|---|---|---|---|---|
| Q12 (50.5 to < 126.8 ng/mL) | Q2 (≥ 126.8 to < 141.9 ng/mL) | Q3 (≥ 141.9 to < 158 ng/mL) | Q4 (≥ 158 to 253 ng/mL) | P for trend3 | |
| Median (ng/mL) | 113.7 | 135.3 | 149.4 | 170.4 | |
| Overall | |||||
| Controls (n) | 219 | 220 | 220 | 220 | |
| Cases (n) | 195 | 189 | 198 | 142 | |
| OR | 1.00 | 0.95 | 1.13 | 0.84 | 0.70 |
| 95% CI | — | 0.72, 1.27 | 0.85, 1.51 | 0.62, 1.14 | |
| Nonadvanced4 | |||||
| Cases (n) | 118 | 118 | 111 | 88 | |
| OR | 1.00 | 0.98 | 1.03 | 0.85 | 0.61 |
| 95% CI | — | 0.70, 1.37 | 0.73, 1.46 | 0.60, 1.22 | |
| Advanced5 | |||||
| Cases (n) | 72 | 71 | 84 | 51 | |
| OR | 1.00 | 0.97 | 1.31 | 0.84 | 0.73 |
| 95% CI | — | 0.65, 1.46 | 0.88, 1.95 | 0.54, 1.30 | |
| Stage III or IV | |||||
| Cases (n) | 26 | 19 | 36 | 14 | |
| OR | 1.00 | 0.71 | 1.53 | 0.62 | 0.57 |
| 95% CI | — | 0.37, 1.37 | 0.85, 2.73 | 0.30, 1.29 | |
1
ORs were obtained from multivariate-adjusted conditional logistic regression analysis including age, time since initial screening, year of blood draw, and study center.
2
Reference category.
3
Obtained by using serum selenium as a continuous variable.
4
Defined as stage I or II and Gleason score < 7 (n = 435).
5
Defined as stage III or IV or Gleason score ≥ 7 (n = 278).